Welcome to our dedicated page for Equus Total Return SEC filings (Ticker: EQS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fair-valuing an oil-and-gas subsidiary or deciphering a 200-page Schedule of Investments can slow any review of Equus Total Return’s disclosures. If you have ever searched for “Equus SEC filings explained simply” or wondered how a closed-end fund marks illiquid assets, you know the challenge.
Stock Titan solves that problem. Our platform streams every Equus document the moment it hits EDGAR—whether it is an Equus quarterly earnings report 10-Q filing outlining portfolio valuation shifts, an Equus 8-K material events explained alert on a portfolio company sale, or the latest Equus insider trading Form 4 transactions. AI-powered summaries highlight what moves NAV, flag debt covenant changes and translate complex investment footnotes into plain English. You can even set real-time alerts for Equus Form 4 insider transactions real-time to see when directors buy or sell shares.
Need deeper context? Drill into each filing type below:
- 10-K Annual Report – Our “Equus annual report 10-K simplified” view extracts portfolio composition, valuation techniques and risk factors in minutes.
- 10-Q Quarterly Update – Compare quarter-over-quarter fair-value marks with one-click Equus earnings report filing analysis.
- Form 4 – Track Equus executive stock transactions Form 4 and spot buying ahead of material NAV changes.
- DEF 14A Proxy Statement – Instantly surface Equus proxy statement executive compensation details, including carried-interest metrics.
From understanding Equus SEC documents with AI to monitoring NAV-moving disclosures, Stock Titan delivers complete, real-time coverage so professionals can focus on decisions—not page flipping.
Form 4 insider activity – ClearPoint Neuro, Inc. (CLPT)
Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.
No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.
FAQ
What is the current stock price of Equus Total Return (EQS)?
What is the market cap of Equus Total Return (EQS)?
What is the core business of Equus Total Return Inc?
How does Equus generate returns from its investments?
What kind of companies does Equus Total Return invest in?
What transaction structures are commonly used by Equus?
How does Equus incorporate its subsidiaries into its investment strategy?
What distinguishes Equus Total Return Inc from other investment companies?
How does Equus manage risk in its investment approach?
What role does corporate governance play at Equus Total Return Inc?
